Skip to main content

Advertisement

Table 2 Completed randomized phase II studies with targeted agents in advanced gastric cancer

From: Targeted and novel therapy in advanced gastric cancer

Target Agent Trial Selection biomarker/trial design Progression-free survival benefit/months (experimental versus control)
HER2 Trastuzumab WJOG7112G (T-ACT)/2nd-line [18] HER2/paclitaxel with or without trastuzumab Negative (HR 0.91)/3.68 versus 3.19
Angiogenesis Sorafenib STARGATE/1st-line [80] None/chemotherapy with or without sorafenib Negative (HR 0.92)/5.6 versus 5.3
Ziv-aflibercept MEGA/1st-line [79] None/mFOLFOX6 with ziv-aflibercept or placebo Negative (HR 1.11)/9.7 versus 7.4
Sunitinib NCT01238055/2nd-line [83] None/docetaxel with or without sunitinib Negative (HR 0.77 [95% CI 0.52–1.16])/3.9 versus 2.6 (time to progression)
Regorafenib INTEGRATE/3rd-line [81] None/regorafenib versus placebo Positive (HR 0.40)/2.6 versus 0.9
Ramucirumab RAINSTORM/1st-line [69] HER2(−)/chemotherapy with ramucirumab or placebo in Asian patients Negative (HR 1.07)/6.34 versus 6.74
Ramucirumab NCT01246960/1st-line [65] None/mFOLFOX6 with ramucirumab or placebo Negative (HR 0.98)/6.4 versus 6.7
Pazopanib NCT01503372/1st-line [85] HER2(−)/chemotherapy with or without pazopanib Negative (HR 0.93)/5.1 versus 3.9
FGFR AZD4547 SHINE/2nd-line [112] FGFR/AZD4547 versus paclitaxel Negative (HR 1.57)/1.8 versus 3.5
Claudin 18.2 IMAB362 FAST/1st-line [118] Claudin 18.2 & HER2(−)/chemotherapy with or without IMAB362 Positive (HR 0.44)/7.5 versus 5.3
Smoothened (Hedgehog signaling) Vismodegib NCT00982592/1st-line [129] None/mFOLFOX6 with vismodegib or placebo Negative/7.3 versus 8.0
  1. HER2 human epidermal growth factor receptor 2, HR hazard ratio, mFOLFOX6 5-fluorouracil/leucovorin/oxaliplatin, FGFR fibroblast growth factor receptor